<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Evaluation of <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes and infiltrating immune cell populations in mice after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> strongly implicates a mixture of both pathogenic and regulatory immune cell subsets that affect <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome </plain></SENT>
<SENT sid="1" pm="."><plain>Our goal was to evaluate the contribution of the well-described coinhibitory pathway, programmed <z:hpo ids='HP_0011420'>death</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>)-1, to the development of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:mpath ids='MPATH_124'>Infarct</z:mpath> volumes, functional outcomes, and effects on infiltrating immune cell populations were compared in <z:mp ids='MP_0002169'>wild-type</z:mp> C57BL/6 versus <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1-deficient mice after 60 minutes middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and 96 hours reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The results clearly demonstrate a previously unrecognized activity of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 pathway to limit <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, recruitment of inflammatory cells from the periphery, activation of macrophages and central <z:mp ids='MP_0008912'>nervous</z:mp> system microglia, and functional neurological deficits </plain></SENT>
<SENT sid="4" pm="."><plain>These regulatory functions were associated with increased percentages of circulating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-ligand-1 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-ligand-2 expressing CD19(+) B-cells in blood, the spleen, and central <z:mp ids='MP_0008912'>nervous</z:mp> system with the capacity to inhibit activation of inflammatory T-cells and central <z:mp ids='MP_0008912'>nervous</z:mp> system macrophages and microglial cells through upregulated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Our novel observations are the first to implicate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 signaling as a major protective pathway for limiting central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:mp ids='MP_0001845'>inflammation</z:mp> in middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>This inhibitory circuit would likely be pivotal in reducing <z:hpo ids='HP_0001297'>stroke</z:hpo>-associated Toll-like receptor-2- and Toll like receptor-4-mediated release of neurotoxic factors by activated central <z:mp ids='MP_0008912'>nervous</z:mp> system microglia </plain></SENT>
</text></document>